Ocular Therapeutix (0OT) Stock Overview

A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. More details

0OT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 91.7% below our estimate of its fair value

Revenue is forecast to grow 51.76% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Significant insider selling over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

0OT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW493,174 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

493,174 investors already sharing narratives

View all narratives

Ocular Therapeutix, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ocular Therapeutix
Historical stock prices
Current Share Price	US$8.35
52 Week High	US$13.66
52 Week Low	US$5.68
Beta	0.88
1 Month Change	21.01%
3 Month Change	18.64%
1 Year Change	4.53%
3 Year Change	85.64%
5 Year Change	-25.45%
Change since IPO	-11.48%

Recent updates

Shareholder Returns

	0OT	DE Pharmaceuticals	DE Market
7D	-1.2%	5.5%	3.8%
1Y	4.5%	55.2%	3.9%

Return vs Industry: 0OT underperformed the German Pharmaceuticals industry which returned 56.9% over the past year.

Return vs Market: 0OT exceeded the German Market which returned 2.6% over the past year.

Price Volatility

Is 0OT's price volatile compared to industry and market?
0OT volatility
0OT Average Weekly Movement	7.7%
Pharmaceuticals Industry Average Movement	5.6%
Market Average Movement	5.6%
10% most volatile stocks in DE Market	12.5%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: 0OT has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 0OT's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2006	325	Pravin Dugel	www.ocutx.com

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension.

Ocular Therapeutix, Inc. Fundamentals Summary

How do Ocular Therapeutix's earnings and revenue compare to its market cap?
0OT fundamental statistics
Market cap	€1.85b
Earnings (TTM)	-€253.98m
Revenue (TTM)	€45.50m

40.6x

P/S Ratio

-7.3x

P/E Ratio

Is 0OT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0OT income statement (TTM)
Revenue	US$52.04m
Cost of Revenue	US$227.09m
Gross Profit	-US$175.05m
Other Expenses	US$115.44m
Earnings	-US$290.50m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.33
Gross Margin	-336.40%
Net Profit Margin	-558.24%
Debt/Equity Ratio	12.4%

How did 0OT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/03 04:43
End of Day Share Price	2026/07/03 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ocular Therapeutix, Inc. is covered by 26 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Colleen Kusy	Baird
Anita Dushyanth	Berenberg
Tazeen Ahmad	BofA Global Research

Ocular Therapeutix (0OT) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Ocular Therapeutix, Inc. Competitors

Dermapharm Holding

PEPTONIC medical

MPH Health Care

Bayer

Price History & Performance

Recent News & Updates

Ocular Therapeutix, Inc. Appoints Jason Robins as Chief Financial Officer

Ocular Therapeutix, Inc., Annual General Meeting, Jun 10, 2026

Ocular Therapeutix, Inc. Announces First Patient Enrolled in Sol-X Long-Term Extension Trial for Axpaxli in Wet AMD

Ocular Therapeutix, Inc. to Report Q1, 2026 Results on May 05, 2026

Ocular Therapeutix Inc Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD

Ocular Therapeutix, Inc. Announces Chief Financial Officer Changes, Effective January 20, 2026

Recent updates

Ocular Therapeutix, Inc. Appoints Jason Robins as Chief Financial Officer

Ocular Therapeutix, Inc., Annual General Meeting, Jun 10, 2026

Ocular Therapeutix, Inc. Announces First Patient Enrolled in Sol-X Long-Term Extension Trial for Axpaxli in Wet AMD

Ocular Therapeutix, Inc. to Report Q1, 2026 Results on May 05, 2026

Ocular Therapeutix Inc Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD

Ocular Therapeutix, Inc. Announces Chief Financial Officer Changes, Effective January 20, 2026

Ocular Therapeutix, Inc. Appoints David W. Robinson As Global Chief Commercial Officer

Ocular Therapeutics, Inc. Prepares for Database Lock for Its Sol-1 Phase 3 Clinical Trial of Axpaxli

Ocular Therapeutix, Inc. Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI in Wet AMD

Ocular Therapeutics, Inc. Intends to submit New Drug Application for its Product Candidate AXPAXLI

Ocular Therapeutix™? Announces First Patient Randomized in Helios-3 Phase 3 Registrational Program for Axpaxli™? in Npdr

Ocular Therapeutix, Inc. Achieves Target Randomization of 555 Subjects in SOL-R

Ocular Therapeutix, Inc. to Report Q3, 2025 Results on Nov 04, 2025

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $474.999996 million.

Ocular Therapeutix, Inc. to Report Q2, 2025 Results on Aug 05, 2025

Ocular Therapeutix, Inc.(NasdaqGM:OCUL) dropped from Russell 3000E Growth Index

Ocular Therapeutix, Inc. to Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™? in Wet Age-Related Macular Degeneration

Ocular Therapeutix, Inc., Annual General Meeting, Jun 11, 2025

Ocular Therapeutix, Inc. to Report Q1, 2025 Results on May 05, 2025

Ocular Therapeutix Shares Sol-R Enrollment Progress and Next Steps for Axpaxli in NPDR

Ocular Therapeutix Announces More Than 300 Subjects Randomized in Sol-1

New minor risk - Insider selling

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.006 loss in 3Q 2023)

Ocular Therapeutix, Inc. Appoints Namrata Saroj, OD, as Chief Business Officer

Ocular Therapeutix, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Ocular Therapeutix, Inc. Announces Accelerated Timelines for Sol-1 Registrational Trial of AXPAXLI in Wet AMD

Now 22% undervalued

Now 23% undervalued

Executive Chairman recently sold €168k worth of stock

Second quarter 2024 earnings released: US$0.26 loss per share (vs US$0.27 loss in 2Q 2023)

Ocular Therapeutix, Inc. Announces Fda Feedback That Sol-R Trial Is Appropriate as A Registrational Study in Wet Amd

Ocular Therapeutix, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Ocular Therapeutix, Inc. Announces First Patients Enrolled in Phase 3 Sol-R Wet AMD Study

Executive Chairman recently sold €116k worth of stock

First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.39 loss in 1Q 2023)

Ocular Therapeutix, Inc. to Report Q1, 2024 Results on May 07, 2024

Ocular Therapeutix, Inc., Annual General Meeting, Jun 12, 2024

Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix, Inc. Announces CEO Changes

Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

New major risk - Shareholder dilution

Full year 2023 earnings released: US$1.01 loss per share (vs US$0.92 loss in FY 2022)

Ocular Therapeutix, Inc. to Report Q4, 2023 Results on Mar 11, 2024

Ocular Therapeutix, Inc. Announces Management Changes

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA

Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer

President recently sold €84k worth of stock

Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment (Spa) for Pivotal Clinical Trial of Axpaxli in Wet AMD

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

Ocular Therapeutix, Inc. has filed a Follow-on Equity Offering.

New minor risk - Profitability

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.006 loss per share (vs US$0.31 loss in 3Q 2022)

Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

AffaMed Therapeutics Announces Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery

Ocular Therapeutix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Ocular Therapeutix, Inc. Announces Initiation of Its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

Ocular Therapeutix, Inc. Submits Request for Special Protocol Assessment to the U.S. Food and Drug Administration

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.24 loss in 2Q 2022)

Ocular Therapeutix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Ocular Therapeutix™ Announces Appointment of Adrienne L. Graves as New Board Member